ANRS 12300 Reflate TB2: RAL + 3TC/TDF Does Not Achieve Noninferior Efficacy vs EFV + 3TC/TDF at Wk 48 in ART-Naive Adults With HIV and TB

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

Christine Katlama, MD Released: January 4, 2023

Dr Melissa Badowski shares key data about the causes of and recommendations for managing ART failure, from Clinical Care Options (CCO)

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Princy N. Kumar, MD, FIDSA, MACP Mary W. Montgomery, MD David A. Wohl, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Dr Babafemi Taiwo discusses the emergence of lenacapavir for the treatment of multidrug-resistant HIV, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: December 19, 2022